scholarly journals Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability

Oncogene ◽  
2004 ◽  
Vol 23 (3) ◽  
pp. 639-645 ◽  
Author(s):  
Yurij Ionov ◽  
Norma Nowak ◽  
Manuel Perucho ◽  
Sanford Markowitz ◽  
John K Cowell
Neoplasia ◽  
2009 ◽  
Vol 11 (11) ◽  
pp. 1116-IN2 ◽  
Author(s):  
Eftychia Oikonomou ◽  
Eleni Makrodouli ◽  
Maria Evagelidou ◽  
Tobias Joyce ◽  
Lesley Probert ◽  
...  

2011 ◽  
Vol 286 (18) ◽  
pp. 16082-16090 ◽  
Author(s):  
Xiao-Qiong Liu ◽  
Ashwani Rajput ◽  
Liying Geng ◽  
Melanie Ongchin ◽  
Anathbandhu Chaudhuri ◽  
...  

Microsatellite instability (MSI), which occurs in 15% of colorectal cancer, has been shown to have a lower incidence of metastasis and better patient survival rates compared with microsatellite stable colorectal cancer. However, a mechanistic understanding of the basis for this difference is very limited. Here, we show that restoration of TGFβ signaling by re-expression of TGFβ receptor II in MSI colon cancer cells increased PI3K/AKT activation, conferred resistance to growth factor deprivation stress-induced apoptosis, and promoted cell motility in vitro. Treatment with a potent PI3K inhibitor (LY294002) blocked the prosurvival and promotility effects of TGFβ, indicating that TGFβ-mediated promotion of cell survival and motility is dependent upon activation of the PI3K/AKT pathway. Analysis of apoptotic effectors that are affected by TGFβ signaling indicated that Bim is an effector of TGFβ-mediated survival. In addition, TGFβ-induced down-regulation of E-cadherin contributed to the prosurvival effect of TGFβ, and restoration of TGFβ signaling in MSI colon cancer cells increased liver metastasis in an orthotopic model in vivo. Taken together, our results demonstrate that restoration of TGFβ signaling promotes cell survival, motility, and metastatic progression in MSI colon cancer cells and indicate that TGFβ receptor II mutations contribute to the favorable outcomes in colon cancer patients with MSI.


Science ◽  
1995 ◽  
Vol 268 (5215) ◽  
pp. 1336-1338 ◽  
Author(s):  
S Markowitz ◽  
J Wang ◽  
L Myeroff ◽  
R Parsons ◽  
L Sun ◽  
...  

2010 ◽  
Vol 138 (4) ◽  
pp. 1406-1417 ◽  
Author(s):  
Maria S. Pino ◽  
Hirotoshi Kikuchi ◽  
Min Zeng ◽  
Maria–Teresa Herraiz ◽  
Isabella Sperduti ◽  
...  

Author(s):  
Qizhi Liu ◽  
Cheng Xin ◽  
Yikuan Chen ◽  
Jiawen Yang ◽  
Yingying Chen ◽  
...  

BackgroundCetuximab is an effective antibody to treat colorectal cancer (CRC) by targeting the epidermal growth factor receptor (EGFR). However, the mechanisms of acquired resistance to cetuximab therapy, especially in patients without identifiable gene mutations, are not fully understood.MethodsOur study investigated the role of pumilio RNA-binding family member 1 (PUM1) in cetuximab resistance. We established cetuximab-resistant colon cancer cell lines SW480R and Caco-2R and knocked out PUM1 and DEAD-box helicase 5 (DDX5) with the clustered regularly interspaced short palindromic repeats (CRISPR)-caspase 9 (Cas9) system. To check cell proliferation, we used Cell Counting Kit-8. We performed qPCR and immunoblot to examine the levels of mRNAs and proteins for each cell line.ResultsOur data showed that PUM1 was upregulated in SW480R and Caco-2R cells with increased protein levels and cell proliferation, and PUM1 knockout reduced cell viability in the presence of cetuximab. We also found that PUM1 interacted with DDX5 in 3′ untranslated region (UTR) and positively regulated its mRNA expression. Furthermore, suppression of DDX5 also decreased the proliferation of SW480R and Caco-2R cells.ConclusionOur study suggests that PUM1 positively regulates DDX5 and acts as a promoter in cetuximab-resistant colon cancer cells.


Oncotarget ◽  
2016 ◽  
Vol 7 (35) ◽  
pp. 57066-57076 ◽  
Author(s):  
Bo Young Oh ◽  
So-Young Kim ◽  
Yeo Song Lee ◽  
Hye Kyung Hong ◽  
Tae Won Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document